[Methylation Status of the SOCS3 Gene Promoter in H2228 Cells and EML4-ALK-positive Lung Cancer Tissues]

Zhongguo Fei Ai Za Zhi. 2016 Sep 20;19(9):565-70. doi: 10.3779/j.issn.1009-3419.2016.09.01.
[Article in Chinese]

Abstract

Background: The EML4-ALK fusion gene is a newly discovered driver gene of non-small cell lung cancer and exhibits special clinical and pathological features. The JAK-STAT signaling pathway, an important downstream signaling pathway of EML4-ALK, is aberrantly sustained and activated in EML4-ALK-positive lung cancer cells fusion gene, but the underlying reason remains unknown. The suppressor of cytokine signaling (SOCS) is a negative regulatory factor that mainly inhibits the proliferation, differentiation, and induction of apoptotic cells by inhibiting the JAK-STAT signaling pathway. The aberrant methylation of the SOCS gene leads to inactivation of tumors and abnormal activation of the JAK2-STAT signaling pathway. The aim of this study is to investigate the methylation status of the SOCS3 promoter in EML4-ALK-positive H2228 cells and lung cancer tissues.

Methods: The methylation status of the SOCS3 promoter in EML4-ALK-positive H2228 lung cancer cells and lung cancer tissues was detected by methylation-specific PCR (MSP) analysis and verified by DNA sequencing. The expression levels of SOCS3 in H2228 cells were detected by Western blot and Real-time PCR analyses after treatment with the DNA methyltransferase inhibitor 5'-Aza-dC.

Results: MSP and DNA sequencing assay results indicated the presence of SOCS3 promoter methylation in H2228 cells as well as in three cases of seven EML4-ALK-positive lung cancer tissues. The expression level of SOCS3 significantly increased in H2228 cells after 5'-Aza-dC treatment.

Conclusions: The aerrant methylation of the SOCS3 promoter region in EML4-ALK (+) H2228 cells and lung cancer tissues may be significantly involved in the pathogenesis of EML4-ALK-positive lung cancer.

背景与目的 人类棘皮动物微管相关蛋白样4(echinoderm microtubule-associated-protein-like 4, EML4)和人类间变性淋巴瘤激酶(anaplastic lymphoma kinase, ALK)融合基因EML4-ALK是新发现的非小细胞肺癌的驱动基因,患者具有独特的临床病理生理特征,ALK基因下游信号通路的异常持续激活是其重要的下游信号通路,而导致其下游基因持续激活的原因不明。细胞因子信号转导抑制因子(suppressor of cytokine signaling, SOCS)是一类在细胞信号转导过程中起重要作用的负调控因子,主要通过抑制JAK蛋白酪氨酸激酶(janus protein tyrosine kinase, JAK)信号传导和转录激活因子(signal transducer and activator of transcription, STAT)即JAK-STAT等信号通路来调控细胞的增殖、分化和凋亡。肿瘤中常存在SOCS基因的甲基化异常导致的失活,从而导致JAK2-STAT等信号通路持续异常活化。本研究的目的在于探讨EML4-ALK阳性H2228细胞和肺癌组织中SOCS3启动子区甲基化状态。方法 甲基化特异性PCR检测EML4-ALK阳性H2228肺癌细胞及肺癌组织中SOCS3启动子区的甲基化状态,并通过测序验证。DNA甲基转移酶抑制剂5’-Aza-dC处理H2228细胞,并通过Real-time PCR和Western blot检测SOCS3的表达水平变化。结果 MSP及测序分析发现EML4-ALK阳性细胞株H2228中存在SOCS3启动子区甲基化;7例EML4-ALK阳性肺癌组织中的3例存在SOCS3启动子区甲基化,H2228细胞经过5’-Aza-dC去甲基化处理后SOCS3的表达明显增加。结论 EML4-ALK(+)的H2228肺癌细胞及部分肺癌组织中存在SOCS3启动子区的异常甲基化,可能是EML4-ALK阳性肺癌的重要发病机制。.

MeSH terms

  • Cell Line, Tumor
  • Cell Proliferation
  • DNA Methylation
  • Humans
  • Lung Neoplasms / genetics*
  • Lung Neoplasms / metabolism
  • Methylation
  • Oncogene Proteins, Fusion / genetics
  • Oncogene Proteins, Fusion / metabolism*
  • Promoter Regions, Genetic*
  • Suppressor of Cytokine Signaling 3 Protein / genetics*
  • Suppressor of Cytokine Signaling 3 Protein / metabolism

Substances

  • EML4-ALK fusion protein, human
  • Oncogene Proteins, Fusion
  • SOCS3 protein, human
  • Suppressor of Cytokine Signaling 3 Protein

Grants and funding

本研究受国家自然科学基金项目(No.81172233和No.81372306)、天津自然科学基金重点项目(No.12JCZDJC24400和No.16JCZDJC34200)、天津自然科学基金项目(No.13JCYBJC22600)、天津市科委抗癌重大专项攻关计划(No.12ZCDZSY16100)、教育部博士点基金(No.20131202110004)资助